Categories: NewsPatient Care

Sonendo Launches ProControlTM for the GentleWave® G4 System

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Sonendo, Inc. (OTCQX:SONX) (“Sonendo”), a leading dental technology company and developer of the GentleWave® System, today announced the launch of ProControl™ as the Company’s latest advancement in endodontic care. The ProControl software update enables optimized cleaning of complex anatomy and increased procedure efficiency.


ProControl allows endodontists to adjust procedure fluid concentration levels when using the CleanFlowTM procedure instrument, tailoring treatments to each patient’s unique needs. This advancement expands the clinical flexibility for the GentleWave G4 System enabling optimal clinical outcomes and an improved patient experience through personalized treatment.

“ProControl for the GentleWave G4 represents our commitment to continued product innovation,” said Bjarne Bergheim, President and Chief Executive Officer of Sonendo. “The GentleWave G4 Console was designed with the future in mind, and this upgrade will allow our G4 users the opportunity to reduce procedure time and further facilitate the transition towards non-instrumentation endodontics. No other endodontic system can automatically and precisely adjust fluid concentrations during treatment. Sonendo remains dedicated to meeting the evolving needs of endodontists and their patients by advancing dental care through technology. With the launch of ProControl, we are thrilled to be providing our customers the ability to fine-tune patient care.”

Kevin Yein, Vice President of R&D, added, “We are excited to introduce ProControl as part of our ongoing commitment to evolving endodontic innovation to provide more personalized care for patients. Our G4 technology underscores our dedication to providing endodontists with the tools to help them transform root canal treatment within their practices and provide better care to their patients.”

ProControl for the GentleWave G4 system is available now. For more information about the GentleWave G4 with ProControl or to schedule a demonstration, please visit www.sonendo.com or contact your local sales representative to learn more.

About Sonendo

Sonendo is a commercial-stage medical technology company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy, and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave® System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave® System can improve the workflow and economics of dental practices and offers patients an effective, less invasive, and less painful alternative to traditional root canal therapy.

Forward-Looking Statements

This press release includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, express or implied forward-looking statements relating to the Company’s anticipated business and financial performance on an on-going basis. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions; speak only as of the date they are made; and, as a result, are subject to risks and uncertainties that may change at any time. Factors that could cause the Company’s actual results to differ materially from these forward-looking statements are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission, including the “Risk Factors” set forth in our Annual Report on Form 10-K, as supplemented by our quarterly reports on Form 10-Q. Such filings are available on our website or at www.sec.gov. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts

Investor Contact:
Gilmartin Group

Greg Chodaczek

IR@Sonendo.com

Staff

Recent Posts

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…

35 minutes ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

36 minutes ago

The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids

This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…

39 minutes ago

Honeycomb Clinic Positions for Public Offering

Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…

39 minutes ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…

39 minutes ago

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson’s Disease

MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…

39 minutes ago